Shares of Edwards Lifesciences Corp (NYSE:EW) have earned a consensus recommendation of “Buy” from the twenty-five analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $81.33.

Several analysts have commented on EW shares. Cowen dropped their target price on shares of Edwards Lifesciences from $91.67 to $83.33 and set an “outperform” rating for the company in a research report on Monday, April 20th. Raymond James upped their target price on shares of Edwards Lifesciences from $76.67 to $83.33 and gave the company an “outperform” rating in a research report on Friday, April 24th. Stifel Nicolaus upped their target price on shares of Edwards Lifesciences from $76.67 to $85.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Canaccord Genuity reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Friday, April 24th. Finally, BTIG Research reiterated a “hold” rating on shares of Edwards Lifesciences in a research report on Thursday, April 23rd.

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 3,470 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $223.50, for a total transaction of $775,545.00. Following the completion of the transaction, the vice president now owns 45,401 shares in the company, valued at approximately $10,147,123.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 26,700 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $69.51, for a total value of $1,855,917.00. Following the transaction, the chief financial officer now owns 27,114 shares of the company’s stock, valued at approximately $1,884,694.14. The disclosure for this sale can be found here. In the last quarter, insiders have sold 194,323 shares of company stock valued at $25,124,106. Corporate insiders own 1.48% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. lifted its stake in Edwards Lifesciences by 2.5% in the 1st quarter. BlackRock Inc. now owns 18,659,731 shares of the medical research company’s stock valued at $3,519,597,000 after purchasing an additional 458,932 shares during the last quarter. State Street Corp lifted its stake in Edwards Lifesciences by 0.9% in the 1st quarter. State Street Corp now owns 8,998,907 shares of the medical research company’s stock valued at $1,697,374,000 after purchasing an additional 81,976 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Edwards Lifesciences by 5.6% in the 1st quarter. Bank of New York Mellon Corp now owns 6,550,480 shares of the medical research company’s stock valued at $1,235,552,000 after purchasing an additional 346,555 shares during the last quarter. Wellington Management Group LLP lifted its stake in Edwards Lifesciences by 43.5% in the 1st quarter. Wellington Management Group LLP now owns 6,404,218 shares of the medical research company’s stock valued at $1,207,965,000 after purchasing an additional 1,940,741 shares during the last quarter. Finally, Capital International Investors lifted its stake in Edwards Lifesciences by 15.9% in the 1st quarter. Capital International Investors now owns 5,165,441 shares of the medical research company’s stock valued at $974,305,000 after purchasing an additional 707,457 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

NYSE:EW traded up $0.76 during trading hours on Tuesday, hitting $67.89. 2,380,300 shares of the stock were exchanged, compared to its average volume of 4,397,997. The company’s 50 day moving average is $109.78 and its two-hundred day moving average is $81.98. Edwards Lifesciences has a twelve month low of $51.51 and a twelve month high of $82.55. The company has a quick ratio of 2.47, a current ratio of 3.36 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $41.60 billion, a P/E ratio of 38.94, a price-to-earnings-growth ratio of 2.53 and a beta of 0.84.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. Edwards Lifesciences had a return on equity of 31.83% and a net margin of 24.71%. The firm had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the prior year, the business earned $0.44 EPS. The business’s revenue for the quarter was up 13.7% compared to the same quarter last year. On average, equities research analysts expect that Edwards Lifesciences will post 1.65 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: What are the economic characteristics of a bear market?

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.